Aptevo Non Current Liabilities Other from 2010 to 2024

APVO Stock  USD 0.34  0.03  9.68%   
Aptevo Therapeutics Non Current Liabilities Other yearly trend continues to be very stable with very little volatility. Non Current Liabilities Other is likely to grow to about 18.8 M this year. During the period from 2010 to 2024, Aptevo Therapeutics Non Current Liabilities Other quarterly data regression pattern had sample variance of 61.7 T and median of  469,000. View All Fundamentals
 
Non Current Liabilities Other  
First Reported
2016-06-30
Previous Quarter
14 K
Current Value
14 K
Quarterly Volatility
M
 
Covid
Check Aptevo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aptevo Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 538.6 K, Interest Expense of 43.1 M or Selling General Administrative of 19.2 M, as well as many indicators such as Price To Sales Ratio of 4.17, Dividend Yield of 0.0 or PTB Ratio of 0.16. Aptevo financial statements analysis is a perfect complement when working with Aptevo Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Aptevo Therapeutics Correlation against competitors.
To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.

Latest Aptevo Therapeutics' Non Current Liabilities Other Growth Pattern

Below is the plot of the Non Current Liabilities Other of Aptevo Therapeutics over the last few years. It is Aptevo Therapeutics' Non Current Liabilities Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aptevo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Non Current Liabilities Other10 Years Trend
Slightly volatile
   Non Current Liabilities Other   
       Timeline  

Aptevo Non Current Liabilities Other Regression Statistics

Arithmetic Mean6,067,590
Geometric Mean1,709,336
Coefficient Of Variation129.48
Mean Deviation7,084,253
Median469,000
Standard Deviation7,856,317
Sample Variance61.7T
Range18.6M
R-Value0.85
Mean Square Error18T
R-Squared0.73
Significance0.000052
Slope1,499,550
Total Sum of Squares864.1T

Aptevo Non Current Liabilities Other History

202418.8 M
202317.9 M
202015.6 M
20193.3 M
2018200 K
2017734 K

About Aptevo Therapeutics Financial Statements

Aptevo Therapeutics investors utilize fundamental indicators, such as Non Current Liabilities Other, to predict how Aptevo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Non Current Liabilities Other17.9 M18.8 M

Pair Trading with Aptevo Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptevo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptevo Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Aptevo Stock

  0.43KZR Kezar Life SciencesPairCorr
  0.34A Agilent Technologies Sell-off TrendPairCorr
The ability to find closely correlated positions to Aptevo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptevo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptevo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptevo Therapeutics to buy it.
The correlation of Aptevo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptevo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptevo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptevo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Aptevo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptevo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptevo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptevo Therapeutics Stock:
Check out the analysis of Aptevo Therapeutics Correlation against competitors.
To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(11.24)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.73)
Return On Equity
(2.51)
The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptevo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.